Literature DB >> 16192536

Sevoflurane pretreatment inhibits endotoxin-induced shock in rats.

Yoko Kidani1, Takumi Taniguchi, Hiroko Kanakura, Yasuhiro Takemoto, Kazunobu Tsuda, Ken Yamamoto.   

Abstract

UNLABELLED: We examined the effects of sevoflurane pretreatment on mortality and inflammatory responses during endotoxin-induced shock. Rats were allocated randomly to 1 of 4 groups (n = 12 per group): an endotoxemia group, receiving IV Escherichia coli endotoxin (15 mg/kg over 2 min); a saline control group, receiving 0.9% saline (1.0 mL/kg); a sevoflurane-only group, receiving 2.4% sevoflurane for 30 min immediately before injection of 0.9% saline; and a sevoflurane pretreatment group, receiving 2.4% sevoflurane for 30 min immediately before injection of endotoxin. Hemodynamic variables, arterial blood gases, and plasma concentrations of tumor necrosis factor-alpha and interleukin-6 were measured. The 8-h mortality rate was determined. Systolic arterial blood pressure and acid-base balance improved with sevoflurane pretreatment before induction of endotoxemia. Mortality rates 8 h after endotoxin injection were 83%, 8%, 0%, and 25% for the endotoxemia, saline control, sevoflurane-only, and sevoflurane pretreatment groups, respectively. Plasma cytokine concentrations were significantly larger in the endotoxemia group than in the other groups. Sevoflurane pretreatment inhibited inflammatory responses and decreased mortality in rats exposed to endotoxin. IMPLICATIONS: Sevoflurane pretreatment decreased mortality rate, severity of hypotension, and acidosis, and inhibited cytokine responses in rats injected with endotoxin, suggesting that sevoflurane may be an anesthetic of choice in endotoxemic states.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16192536     DOI: 10.1213/01.ane.0000167768.55939.e1

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  8 in total

Review 1.  Sepsis pathophysiology and anesthetic consideration.

Authors:  Koichi Yuki; Naoka Murakami
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2015

2.  Sevoflurane combined with ATP activates caspase-1 and triggers caspase-1-dependent pyroptosis in murine J774 macrophages.

Authors:  Yue Jin; Hui Li; Guohao Xie; Shuzhen Chen; Shuijin Wu; Xiangming Fang
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

3.  Sevoflurane binds and allosterically blocks integrin lymphocyte function-associated antigen-1.

Authors:  Koichi Yuki; Nathan S Astrof; Clay Bracken; Sulpicio G Soriano; Motomu Shimaoka
Journal:  Anesthesiology       Date:  2010-09       Impact factor: 7.892

4.  Lipopolysaccharide directly alters renal tubule transport through distinct TLR4-dependent pathways in basolateral and apical membranes.

Authors:  David W Good; Thampi George; Bruns A Watts
Journal:  Am J Physiol Renal Physiol       Date:  2009-07-22

5.  Deep anesthesia worsens outcome of rats with inflammatory responses.

Authors:  Kei Inoue; Takeshi Suzuki; Toru Igarashi; Shizuka Minamishima; Hiroyuki Seki; Shizuko Kosugi; Nobuyuki Katori; Hiroshi Morisaki
Journal:  Inflamm Res       Date:  2016-03-21       Impact factor: 4.575

6.  The volatile anesthetic sevoflurane attenuates ventilator-induced lung injury through inhibition of ERK1/2 and Akt signal transduction.

Authors:  Sang-Hun Kim; Mei Li; Tae-Hee Pyeon; Keum-Young So; Sang-Hyun Kwak
Journal:  Korean J Anesthesiol       Date:  2015-01-28

7.  Effects of sevoflurane postconditioning on cell death, inflammation and TLR expression in human endothelial cells exposed to LPS.

Authors:  Raquel Rodríguez-González; Aurora Baluja; Sonia Veiras Del Río; Alfonso Rodríguez; Jaime Rodríguez; Manuel Taboada; David Brea; Julián Álvarez
Journal:  J Transl Med       Date:  2013-04-03       Impact factor: 5.531

8.  Plasma kynurenic acid concentration in patients undergoing cardiac surgery: effect of anaesthesia.

Authors:  Edyta Kotlinska-Hasiec; Patrycja Nowicka-Stazka; Jolanta Parada-Turska; Krzysztof Stazka; Janusz Stazka; Przemyslaw Zadora; Wojciech Dabrowski
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-09-10       Impact factor: 4.291

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.